Source-grounded facts extracted from Launch One Acquisition Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Daniel Clifford Rogers was appointed as Director and chairperson of the audit committee at Launch One Acquisition Corp..
“June 2, 2026, the board of directors (the " Board ") of Launch One Acquisition Corp. (the " Company ") appointed Daniel Clifford Rogers as a member of the Board. Mr. Rogers was appointed as a replacement for Dr. Risa Stack, who resigned from the Board and as chairperson of the audit committee of the Board (the " Audit Committee "), and as a member of the compensation committee of the Board, effective as of the same date.”
Risa Stack resigned as Director and chairperson of the audit committee at Launch One Acquisition Corp..
“June 2, 2026, the board of directors (the " Board ") of Launch One Acquisition Corp. (the " Company ") appointed Daniel Clifford Rogers as a member of the Board. Mr. Rogers was appointed as a replacement for Dr. Risa Stack, who resigned from the Board and as chairperson of the audit committee of the Board (the " Audit Committee "), and as a member of the compensation committee of the Board, effective as of the same date.”
Debt Financings
Launch One Acquisition Corp. incurred loan of up to $1,000,000 with Launch One Sponsor, LLC at annual interest of 8%, with a default interest rate of an additional 18% (for a maturing the consummation of the Company’s initial business combination or the effective date of the winding up of the Company (or if earlier, upon an event of default).
“On March 20, 2026, Launch One Acquisition Corp. (the “ Company ”), entered into a Working Capital Promissory Note (the “ Working Capital Note ”) with Launch One Sponsor, LLC (the “ Sponsor ”), the sponsor of the Company, pursuant to which the Sponsor may loan up to $1,000,000 to the Company in up to three tranches”
Material Agreements
Launch One Acquisition Corp. terminated Business Combination Agreement with Minovia Therapeutics Ltd. valued at Termination and Release Agreement entered into on January 30, 2026 mutually terminating the Business (effective 2026-01-30).
“Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed, Launch One Acquisition Corp. (the “ Company ”) entered into a Business Combination Agreement, dated as of June 25, 2025, as amended on August 12, 2025, September 4, 2025, September 26, 2025 and January 6, 2026 (collectively, the “ BCA ”) with (i) Launch One Sponsor LLC, a Delaware limited liability company, in the capacity as the SPAC Representative (as defined in the BCA) under the BCA (the “ SPAC Representative ”), (ii) Minovia Therapeutics Ltd., an Israeli company limited by shares (“ Minovia ”), (iii) Natalie Yivgi-Ohana, in the capacity as the Seller Representative (as defined in the BCA) under the BCA (the “ Seller Representative ”), (iv) Mito US One Ltd., an Israeli company limited by shares (“ Pubco ”), and (v) Mito Sub Israel Ltd., an Israeli company limited by shares and a wholly-owned subsidiary of Pubco (“ Company Merger Sub ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.